This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): RBX, LY333531, Ruboxistaurin mesylate
Description: Arxxant is a selective inhibitor of protein kinase C (PKC) beta. Increased activation of specific PKC isoforms are mechanistic pathways implicated in the pathogenesis of diabetic complications, including microvascular damage and albuminuria.
Deal Structure: In December 2003, Eli Lilly and Company Japan K.K., Kobe, Japan and Takeda Chemical Industries, announced that Eli Lilly and Company and Takeda signed an agreement on joint development and co-marketing for ruboxistaurin mesylate (Arxxant) in the Japanese market.
Eli Lilly and Company and Alcon announced in July 2006 that they have signed a long-term agreement to co-promote Arxxant in the U.S. and Puerto Rico. Under the terms of the agreement, Alcon will have primary responsibility for promotion to eye specialists, including retinal specialists and general ophthalmologists, while Lilly will have primary responsibility for promotion to endocrinologists and primary care physicians. Alcon will make milestone and marketing payments to Lilly and Alcon will be compensated based on product sales.
In August 2007, Eli Lilly Japan and Takeda Pharmaceutical jointly announced that the agreement on joint development and co-marketing for Arxxant (ruboxistaurin mesylate) in Japan was...See full deal structure in Biomedtracker
Partners: Novartis AG
Pink Sheet Lilly Arxxant "approvable"
Additional information available to subscribers only: